Survanta market forecast points to growth through 2030
The Survanta market is expanding as premature births rise and neonatal care improves, according to a new forecast from The Business Research Company. North America led in 2025, while Asia-Pacific is projected to grow fastest as NICU access and neonatal treatment capabilities broaden.
Why it matters: - Survanta is used to treat or prevent respiratory distress syndrome in premature infants, making the market closely tied to neonatal survival and care quality. - Rising premature birth rates and wider neonatal treatment access are expected to sustain demand through 2030. - Growth in NICU capacity, neonatal drug delivery, and surfactant therapy could affect hospital purchasing and care protocols across regions.
What happened: - The Business Research Company released a Survanta market forecast on Nov. 12, 2026. - The report covers market size, growth drivers, regional dynamics, trends, and future outlook for the therapy area. - The company says the market is gaining attention because of rising premature birth rates and advances in neonatal care. - A free sample of the report is available. - A full report is also offered.
The details: - Survanta replaces deficient natural surfactant in the lungs, lowers surface tension in the alveoli, improves breathing, and supports oxygen exchange. - The drug is administered directly into the lungs to stabilize respiratory function and support lung development in vulnerable newborns. - Past growth factors included higher premature birth rates, greater awareness of neonatal respiratory distress syndrome, expansion of NICUs, better survival rates for preterm infants, and broader adoption of surfactant therapy. - Forecast-period drivers include more advanced neonatal care technologies, broader access to neonatal healthcare in emerging markets, ongoing lung maturation research, rising demand for early intervention treatments, and better neonatal drug delivery methods. - Key trends include expanded use of surfactant replacement therapies, more focus on neonatal respiratory care, global NICU infrastructure expansion, improved administration techniques for premature infants, and greater standardization of clinical protocols. - Prematurity is defined as birth before 37 weeks of gestation. - The report says rising maternal age, lifestyle factors, chronic health conditions, and fertility treatments are contributing to more premature births. - The CDC recorded a 10.41% US preterm birth rate in 2024. - In September 2024, the American Hospital Association said the US Department of Health and Human Services allocated more than $558 million to maternal health programs, including home visits and CDC initiatives. - UK infant hospital admissions for children under 14 days old rose from 81.6 per 1,000 population in fiscal 2022 to 84.8 per 1,000 in fiscal 2023, according to the Office for Health Improvement and Disparities. - In 2025, North America was the largest Survanta market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also includes Western Europe, Eastern Europe, South America, the Middle East, and Africa.
Between the lines: - The forecast suggests Survanta demand is being shaped less by a single product story and more by broader neonatal health systems, including NICU capacity and access to early treatment. - The strongest regional growth is likely to follow healthcare infrastructure improvements rather than current market size alone. - The added emphasis on standardization and administration techniques points to a market where clinical practice, not just drug volume, may drive adoption.
What's next: - The Business Research Company says its 2026 reports add market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The company is also promoting expert contact channels for buyers seeking more detail on the market outlook.
The bottom line: - Survanta’s market outlook is tied to rising premature births, stronger NICU systems, and broader neonatal care access, with growth expected to be strongest in Asia-Pacific while North America remains the largest market.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Analysis
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.